BRIEF-Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, And Tolerability Study Of SP-26 For Chronic Pain And Fibromyalgia

Reuters
11 Feb
BRIEF-Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, And Tolerability Study Of SP-26 For Chronic Pain And Fibromyalgia

Feb 11 (Reuters) - Silo Pharma SILO.O:

  • SILO PHARMA ANNOUNCES POSITIVE INITIAL PHARMACOKINETIC, SAFETY, AND TOLERABILITY STUDY OF SP-26 FOR CHRONIC PAIN AND FIBROMYALGIA

  • SILO PHARMA INC - NO SERIOUS SIDE EFFECTS OBSERVED IN SP-26 STUDY

  • SILO PHARMA INC - FINAL SAFETY AND ABSORPTION DATA EXPECTED IN MARCH 2025

Source text: ID:nGNX7qL6FT

Further company coverage: SILO.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10